Judge sides with heparin plaintiffs in Baxter case

A state court in Illinois has granted a partial summary judgment to two plaintiffs suing Baxter International over contaminated blood thinner, saying that some of the company's heparin was "unreasonably dangerous." Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.